Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.

MLA

Tsuji, Daiki, et al. “Analysis of Pharmacogenomic Factors for Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer Receiving Doxorubicin and Cyclophosphamide Chemotherapy.” Cancer Chemotherapy and Pharmacology, vol. 87, no. 1, Jan. 2021, pp. 73–83. EBSCOhost, https://doi.org/10.1007/s00280-020-04177-y.

APA

Tsuji, D., Matsumoto, M., Kawasaki, Y., Kim, Y.-I. L., Yamamoto, K., Nakamichi, H., Sahara, Y., Makuta, R., Yokoi, M., Miyagi, T., & Itoh, K. (2021). Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy. Cancer Chemotherapy and Pharmacology, 87(1), 73–83. https://doi.org/10.1007/s00280-020-04177-y

Chicago

Tsuji, Daiki, Megumi Matsumoto, Yohei Kawasaki, Yong-I L Kim, Keisuke Yamamoto, Hidenori Nakamichi, Yuri Sahara, et al. 2021. “Analysis of Pharmacogenomic Factors for Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer Receiving Doxorubicin and Cyclophosphamide Chemotherapy.” Cancer Chemotherapy and Pharmacology 87 (1): 73–83. doi:10.1007/s00280-020-04177-y.